Jovanović J, Cvjetković D, Pobor M, Brkić S
Klinika za infektivne i dermato-veneroloske bolesti, Medicinski fakultet, Novi Sad.
Med Pregl. 1998 Mar-Apr;51(3-4):151-4.
Chickenpox represents the primary form of Varicella-zoster virus (VZV) infection and appears most commonly in preschool and school children. The clinical course of chickenpox in immunocompetent children is mainly mild and complications are rare (1-5). Adults and immunocompromised patients are considered to be risk groups for development of serious and even life-threatening complications. The most frequent bacterial complications include secondary bacterial skin infections, angina, sinusitis, otitis and bronchopneumonia. Central nervous system complications, visceral dissemination, pneumonitis and myocarditis are the major viral complications (6,7). Acyclovir is approved for treatment of chickenpox in risk groups to reduce the frequency of viral complications and to treat those ones which have already appeared (7,8). The treatment of bacterial complications is based on the examination results of the bacterial sensitivity to antibiotics.
In our study patients with the diagnosis of chickenpox based on the history of disease, clinical features and clinical course and data on intimate contact with individuals suffering from chickenpox, were clinically followed-up. Sedimentation rate, blood count and urine samples were analyzed. A unique questionnaire was designed to follow-up the following data: sex, age, course of the disease, occurrence of complications in immunocompetent patients and those belonging to risk groups and effects of acyclovir therapy.
During a three-year period 48 patients with chickenpox treated at the Clinic of Infectious and Dermatovenereology Diseases have been observed. 64.6% of them were males and 35.4% were females. 29.2% were infants under 1 year of age, 29.2% were 2-13 years of age and 41.6% were 14-50 years of age. According to the clinical course, patients were divided into two groups: the first one included patients who developed complications of chickenpox (54.1%), the second one consisted of those without complications (45.1%). 72.7% of all complications occurred in patients belonging to risk group (14-50 years of age). Among viral complications in risk groups the most common were pneumonia (44.4%) and haemorrhagic rash (44.4%), only one patient (11.1%) developed a mild, viral meningitis. Bacterial complications were also present in risk group as secondary bacterial skin infections (71.4%) and otitis media (28.6%). Viral complications were treated successfully by 750 mg intravenous acyclovir given 3 times a day, or by 800 mg oral acyclovir given 5 times a day during 7-10 days. Adequate antibiotics were used in the treatment of bacterial complications. A case of chickenpox associated with the meningitis caused by Haemophilus influenzae was also reviewed.
In this study the majority of observed patients had a mild, clinical form of chickenpox that is in accordance with the other available clinical data (1-4). Complications developed more frequently in the adults and usually were of viral etiology. All patients were on time treated with acyclovir and visceral dissemination did not occur in any of them. Complications had a favourable evolution and VZV meningitis was healed without sequelae. Many authors have written about successful use of acyclovir in the treatment of chickenpox. However, acyclovir is not recommended to immunocompetent persons without chickenpox viral complications who do not belong to risk groups (1,3,4,9-11).
Our findings lead to the conclusion that chickenpox in adults may have an uncertain outcome because of a more severe clinical course and susceptibility to complications. In our study application of acyclovir in that age group provided good results as for prevention and treatment of complications of chickenpox if already manifested.
水痘是水痘-带状疱疹病毒(VZV)感染的主要形式,最常见于学龄前和学龄儿童。免疫功能正常的儿童水痘临床过程主要为轻症,并发症罕见(1 - 5)。成人和免疫功能低下患者被认为是发生严重甚至危及生命并发症的风险人群。最常见的细菌并发症包括继发性细菌性皮肤感染、咽炎、鼻窦炎、中耳炎和支气管肺炎。中枢神经系统并发症、内脏播散、肺炎和心肌炎是主要的病毒并发症(6,7)。阿昔洛韦被批准用于治疗风险人群的水痘,以减少病毒并发症的发生频率,并治疗已出现的并发症(7,8)。细菌并发症的治疗基于细菌对抗生素敏感性的检查结果。
在我们的研究中,根据疾病史、临床特征和临床过程诊断为水痘的患者,以及与水痘患者密切接触的数据,进行了临床随访。分析了血沉、血常规和尿液样本。设计了一份独特的问卷来随访以下数据:性别、年龄、病程、免疫功能正常患者和风险人群中并发症的发生情况以及阿昔洛韦治疗的效果。
在三年期间,观察了48例在传染病和皮肤性病诊所接受治疗的水痘患者。其中64.6%为男性,35.4%为女性。29.2%为1岁以下婴儿,29.2%为2 - 13岁,41.6%为14 - 50岁。根据临床过程,患者分为两组:第一组包括出现水痘并发症的患者(54.1%),第二组为无并发症的患者(45.1%)。所有并发症的72.7%发生在风险人群(14 - 50岁)患者中。在风险人群的病毒并发症中,最常见的是肺炎(44.4%)和出血性皮疹(44.4%),只有1例患者(11.1%)发生了轻度病毒性脑膜炎。风险人群中也存在细菌并发症,如继发性细菌性皮肤感染(71.